Indeed, ALICINA2 clinical trials were started to highlight our previous proof-of-concept study, which focused on the prognostic value of different liquid biopsy biomarkers (CTCs, PD-L1+ CTCs, sEVs, PD-L1+ sEVs, and ctDNA) alone, and in combination, in a cohort of patients with NSCLC, regardless of cancer treatment, subtype, and stage, to determine whether their combination provides more precise prognostic information [233]. This evidence concerns the gene CD274 and cancer.